title: Safety and efficacy of combined clozapine-azathioprine treatment in a case of resistant schizophrenia associated with Behçet's disease: a 2-year follow-up.
abstract: Behçet's disease (BD) is a recurrent inflammatory disorder involving multisystems of the body. Neuropsychiatric symptoms, like psychosis and depression, often occur in BD, but the safety and efficacy of combined clozapine-azathioprine treatment have never been assessed. We here report on a 37-year-old man with BD and treatment-resistant schizophrenia who obtained an improvement following the introduction of clozapine in addition to azathioprine, without developing agranulocytosis or other severe adverse side effects during a 2-year follow-up.
authors: NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital G. Mazzini, ASL 4, 64100 Teramo, Italy. dodebera@aliceposta.it
authors: Domenico
authors: D
authors: De Berardis
authors: Nicola
authors: N
authors: Serroni
authors: Daniela
authors: D
authors: Campanella
authors: Luigi
authors: L
authors: Olivieri
authors: Stefano
authors: S
authors: Marini
authors: Francesco Saverio
authors: FS
authors: Moschetta
authors: Giovanni
authors: G
authors: Martinotti
authors: Massimo
authors: M
authors: Di Giannantonio
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001379:Azathioprine / Q000009:adverse effects*; D001528:Behcet Syndrome / Q000188:drug therapy*; D003024:Clozapine / Q000009:adverse effects*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D007166:Immunosuppressive Agents; D003024:Clozapine; D001379:Azathioprine